In proceedings concerning the determination of the maximum price and the amount and conditions of the first temporary reimbursement for a highly innovative medicinal product (VILP), the State Institute for Drug Control (the Institute) proposed granting reimbursement for the tablet formulation for a period of three years from the date the decision becomes enforceable.
The
reimbursement application concerned a medicinal product in the form of
film-coated tablets. The product is bioequivalent to an oral solution
formulation of the same medicinal product, for which reimbursement had
previously been granted under the procedure for orphan medicinal products
pursuant to Section 39da.
During the proceedings, the Institute refused to include the two formulations in the same reference group on the basis of therapeutic interchangeability. Although the tablets (VILP) and oral solution (orphan medicinal product) contain the same active substance, have the same indication and share the same marketing authorisation holder, the Institute explicitly concluded that the two pharmaceutical forms do not belong to the same group of essentially therapeutically interchangeable medicinal products.
The Institute stated that automatically grouping the VILP and the orphan medicinal product together within a single reference group would undermine the purpose of the separate VILP assessment procedure and circumvent the legislative intent. It therefore established a new, separate group of therapeutically interchangeable medicinal products for the tablet formulation.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
In proceedings
concerning changes to the amount and conditions of reimbursement of a medicinal
product, the applicant requested an extension of the prescribing restrictions
to include medical specialty J9. The State Institute for Drug Control (the
Institute) proposed maintaining the existing reimbursement amount and
conditions and rejecting the application, despite considering the request
clinically justified.
The Institute
acknowledged that physicians working in specialised J9 centres possess the
necessary expertise and provide a higher level of specialised care than the
medical specialties already authorised to prescribe the medicinal product. The
Institute also agreed with the opinions of the Medical Societies supporting the
extension of prescribing rights to specialty J9. It considered the proposed
extension to be administrative and organisational in nature, without expanding
the population of patients eligible for treatment. Therefore, the submission of
pharmacoeconomic analyses was not required.
The reason for
the proposed rejection was that the previously concluded financial
agreements limiting the budget impact covered only the existing scope of
prescribing restrictions. At the time the assessment report was issued, it had
not been demonstrated that these agreements would also apply to the proposed
extension of prescribing rights to specialty J9.
Consequently,
the Institute considered that it had not been sufficiently demonstrated that
extending the prescribing restrictions would not result in increased
expenditure from the public health insurance system.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
The State
Institute for Drug Control (the Institute) determined the first temporary
reimbursement for a highly innovative medicinal product (HIMP) at the lower
reimbursement rate under JUHR2.
When
determining reimbursement for the medicinal product, the Institute proceeded in
accordance with Section 39d(9) of the Public Health Insurance Act by
comparing the reimbursement amount calculated using the standard method (based
on price references) with reimbursement amounts previously established for the
same medicinal product in other administrative proceedings and applying the
lower amount.
Section 39d(9)
of the Public Health Insurance Act states:
“Where
proceedings are conducted to determine temporary reimbursement for a medicinal
product that is already reimbursed under another therapeutic indication through
public health insurance on the basis of a decision issued by the Institute
pursuant to Section 39h, the Institute shall determine the temporary
reimbursement amount at no more than the reimbursement amount established by
the Institute's decision pursuant to Section 39h.This shall
not apply where such a medicinal product has been included, by a decision of
the Institute pursuant to Section 39h, in a reference group or another group of
essentially therapeutically interchangeable medicinal products that already
includes other medicinal products. Where
another highly innovative medicinal product has also been granted temporary
reimbursement and the available evidence demonstrates that it has similar
clinical use and comparable or closely similar efficacy and safety, the
Institute shall determine the temporary reimbursement amount for the medicinal
product under assessment at no more than the temporary reimbursement amount
established for the highly innovative medicinal product with similar clinical
use and comparable or closely similar efficacy and safety, taking into account
differences in dosage and pack size.”
In applying the
above provision, the Institute verified whether the medicinal products were
already reimbursed within the public health insurance system and identified
their applicable reimbursement amounts. It found that, in addition to the
higher JUHR1 reimbursement amount, a lower JUHR2 reimbursement amount was also
in effect. As the
applicable JUHR2 reimbursement amounts for the individual product codes were
lower than those newly calculated on the basis of price references, the
Institute determined reimbursement at the amounts previously established in
proceedings concerning temporary reimbursement of the HIMP for another
indication.
The application
of Section 39d(9) of the Public Health Insurance Act ensured that the newly
determined temporary reimbursement amount for the indication under assessment
did not exceed the previously established, valid and enforceable temporary
reimbursement amount for the same medicinal product in another indication.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
Slovakia has adopted a major
amendment to Act No. 363/2011 Coll., on the Scope and Conditions of
Reimbursement of Medicinal Products, Medical Devices and Dietary Foods under
Public Health Insurance, introducing significant changes to reimbursement
rules, among other areas. The main provisions of the amendment will take effect
on 1 November 2026, while the related implementing decrees will not enter into
force before 1 December 2026.
The following article highlights
selected changes introduced by this legislative amendment.
QALY Thresholds and Clinical
Criteria
The amendment introduces standard
and increased cost-effectiveness thresholds per QALY, with the increased
threshold applying to orphan, innovative and paediatric medicinal products.
Even if a medicinal product does
not meet the GDP-based requirements, it may still exceptionally be included in
the reimbursement system (in the case of orphan drugs, paediatric indications,
innovative treatments or medicinal products for serious diseases), provided
that strict clinical criteria are met.
Managed Entry Agreements
(MEAs) and Applicants' Financial Obligations
Concluding a Managed Entry
Agreement (MEA) is mandatory for the inclusion of a medicinal product in the
reimbursement system if its expected budget impact exceeds EUR 1,500,000 over
12 months or if the product is included under a threshold exemption.
The agreement must cover at least
three reference periods (36 months) and include obligations for the marketing
authorisation holder if the annual reimbursement cap is exceeded or if a
conditional marketing authorisation ceases to be valid. The marketing authorisation
holder must bear the costs of continuing treatment if it unilaterally
terminates the agreement or if the medicinal product is removed from the
reimbursement list due to failure to meet the applicable conditions.
Price Caps and the Entry of
Generics and Biosimilars
The proposed officially
determined price must not exceed the arithmetic mean of the three lowest prices
in EU Member States. For the first generic or
biosimilar medicinal product, mandatory price reductions (percentage discounts)
from the lowest applicable prices are established.
Existing decisions on special
price regulation will expire on 31 December 2026, and prices will be adjusted
to the European reference price level unless an application for a price
adjustment under the new rules has been submitted.
Procedural Rules and
Distribution Regulation
All submissions must be made
exclusively through an electronic portal.
The Ministry of Health will be
authorised to prevent the export of a reimbursed medicinal product if there is
a risk of a critical shortage on the Slovak market.
The main provisions of the
amendment will take effect on 1 November 2026. However, deferred effective
dates apply to certain related pricing and reimbursement mechanisms. Additional implementing
regulations are currently undergoing public consultation. These address, among
other matters, the detailed calculation of the applicable multiple of gross
domestic product (GDP) used to determine the cost-effectiveness threshold for
an assessed medicinal product, as well as the requirements for pharmacoeconomic
evaluations of medicinal products. Their adoption can be expected in the coming
period.
The new rules introduce
changes to pricing and reimbursement requirements for medicinal products in
Slovakia. If you are planning to enter the Slovak market or need support with
pharmacoeconomic analyses and reimbursement submissions, we will be happy to assist
you. Please do not hesitate to contact
us.
Slovakia is continuing to amend its legislative framework governing the reimbursement of medicinal products and medical devices under the public health insurance system. The first changes will take...
The Ministry of
Health (MoH) dismissed an appeal against a decision to discontinue proceedings
concerning the determination of the maximum price and the amount and conditions
of permanent reimbursement due to failure to pay the outstanding balance of administrative
expenses.The appellant had paid the amount corresponding to the fee for an
assessment without a comprehensive evaluation, whereas the State Institute for
Drug Control (the Institute) required payment of the higher fee applicable to a
comprehensive expert assessment. During the appeal proceedings, the MoH
addressed several objections raised by the appellant.
The appellant
argued that the Institute had failed to demonstrate that the conditions for
applying the higher fee for a comprehensive expert assessment had been met.
According to the MoH, the scope of the assessment must be determined
prospectively at the beginning of the proceedings. In the case of a medicinal
product with a new pharmaceutical form and intermittent dosing, entering the
reimbursement system for the first time, the need for a comprehensive clinical
assessment could not be ruled out.
The appellant
further claimed that following the submission of additional documentation and
the narrowing of its reimbursement request (acceptance of the reference group
framework, withdrawal of the request for a reimbursement bonus, and reduction
of the proposed reimbursement amount), a comprehensive assessment was no longer
necessary. The MoH stated that even after these changes, the Institute was
still required to independently assess key clinical parameters, including
therapeutic interchangeability and dosing safety, to determine the product's
inclusion in the reference group. Such an evaluation met the criteria for a
comprehensive assessment.
The appellant
also pointed to changes in the schedule of fees for administrative expenses
during the proceedings. However, according to the MoH, the applicable fee is
determined by the regulations in force when the payment obligation arises, i.e.
on the date the application is submitted.
Finally, the
appellant argued that failure to pay the outstanding balance did not constitute
a material deficiency in the application and that discontinuing the proceedings
was disproportionate. According to the MoH, proof of payment of the legally
prescribed fee is a mandatory requirement of the application, without which the
proceedings cannot continue. The Institute had also provided the appellant with
the necessary assistance and sufficient time to remedy the deficiency. The MoH
therefore found no procedural error on the part of the Institute.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
In proceedings
concerning the determination of the price and reimbursement of a medicinal
product intended for immunisation, the State Institute for Drug Control (the
Institute) clarified its approach to handling information submitted as trade
secrets to substantiate foreign price references.
The Institute
stated that:
to demonstrate the actual manufacturer's price
in a reference country, supporting documents relating to the relevant period
are generally submitted, primarily invoices or other similarly reliable
evidence. Where such evidence is accepted and its content has been submitted as
a trade secret, the Institute takes the substantiated price into account
when determining the price and reimbursement, to the extent necessary to
justify its approach and conclusions, and removes the price used from trade
secret protection.
Where the marketing authorisation holder intends
to demonstrate only a different margin, for example by submitting a
declaration from a third party (such as a distributor) specifying an amount to
be deducted from the identified price, the entire declaration may be
designated as a trade secret.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
In
administrative proceedings concerning changes to the amount and conditions of
reimbursement, the State Institute for Drug Control (the Institute) assessed an
extension and modification of the reimbursement conditions for an oncology
medicinal product.
Before the
third assessment report was issued, the applicant submitted risk-sharing
agreements to the Institute. Although these agreements reduced the overall
budget impact on the public health insurance system, they did not reduce the
actual treatment costs sufficiently to meet the cost-effectiveness
criteria. The resulting incremental cost-effectiveness ratio (ICER) exceeded
the acceptable threshold of CZK 1.2 million per quality-adjusted life year
(QALY). Consequently, in its third assessment report, the Institute concluded
that the cost-effectiveness requirement had not been met and proposed not to
grant reimbursement in subsequent lines of treatment.
In response to
this conclusion, however, new cost-limitation agreements (pricing
agreements ensuring cost-effectiveness) were negotiated and concluded with
health insurance funds. Following the submission of these agreements, the
financial requirements were addressed, resulting in a positive fourth
assessment report recommending that reimbursement be granted.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.
The State
Institute for Drug Control (the Institute) discontinued reimbursement for
specific variants of a medicinal product from the allergen group following an
application by the manufacturer. As part of the
proceedings, the Institute assessed market availability and the public
interest. The analysis confirmed that discontinuing reimbursement would not
put patients at risk, as fully adequate therapeutic alternatives for
the treatment of allergies are available within the relevant therapeutic group.
In assessing
treatment availability and the public interest in connection with the
discontinuation of reimbursement, the Institute considered the following:
1. Statutory
assessment criteria The Institute may
decide to discontinue the amount and conditions of reimbursement if a medicinal
product has not been supplied to the Czech market for more than 12 months and,
at the same time, the discontinuation of reimbursement is not contrary to
the public interest in ensuring access to effective and safe healthcare. Where
the application is submitted by the marketing authorisation holder, the
condition requiring the product to have been absent from the market for 12
months does not have to be met; however, the assessment of the public interest
remains essential.
2. Assessment
of market availability The Institute
examined actual supplies of the medicinal products to the market over the
preceding 12 months. For two of the three product codes, supplies to the
market had been recorded during this period.
3. Therapeutic
alternatives and ensuring access to care The key argument
supporting the conclusion that access to reimbursed healthcare would not be
jeopardised was the availability of alternatives within the same reference
group. The Institute confirmed that other reimbursed medicinal products were
available to patients. In view of this therapeutic
substitutability, the Institute concluded that discontinuing reimbursement
would not affect patients’ access to effective and safe healthcare.
4. Public
interest Based on the
availability of therapeutic alternatives described above, the Institute
concluded that the discontinuation of reimbursement was not contrary to the
public interest.
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of
pharmaceutical and medical device information. We also offer flexible services
that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you
need expert guidance.
A continuously
updated overview of decisions issued by SÚKL and the Ministry of Health in the field
of pricing and reimbursement is available on the Pharmeca a.s. website.
The English translation was prepared using the latest available ChatGPT model.